EUVIMEDEUVIMED entdecken
Multizentrische Studie

Initial Enfortumab Vedotin Dose Reduction and Outcomes in Pretreated Advanced Urothelial Carcinoma

In-Ho Kim, Chang Gon Kim, Jungmin Jo, Eun Hee Jung, Joo-Hwan Park, Woo Kyun Bae, Seok Jae Huh, Yoon Ji Choi, Hyeon-Su Im, Hyo Jin Lee, Kyoungmin Lee, Min-Young Lee und 6 weitere

JAMA Network Open · 2026

DOI: 10.1001/jamanetworkopen.2026.39846 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JAMA Network Open, 2026. Verfasst von In-Ho Kim und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Internal Medicine, Seoul St Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Carcinoma, Transitional Cell, Urologic Neoplasms, Drug Tapering. Die Arbeit nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Initial enfortumab vedotin (EV) dose selection is increasingly relevant in advanced urothelial carcinoma (UC). Reduced starting doses may be selected for some patients, but their associations with clinical outcomes and tolerability remain uncertain.

Objective

To evaluate the association of physician-selected initial EV dose reduction with clinical outcomes among patients with advanced UC. Design, Setting, and Participants This retrospective multicenter cohort study of patients with advanced UC who initiated EV monotherapy after platinum-based chemotherapy and immune checkpoint inhibition was conducted at 18 institutions in Korea from January 1, 2023, to May 31, 2025, with follow-up through May 31, 2026. Data were analyzed in June 2026. Exposures Initial EV dose reduction at first administration, before treatment-related toxicity. The primary comparison was reduced-dose (≥10% reduction) vs full-dose (<10% reduction) EV monotherapy; post hoc analyses used less than 10%, 10% to 20%, and greater than 20% categories. Main Outcomes and Measures Progression-free survival (PFS) and overall survival (OS) were the primary outcomes. Secondary outcomes included objective response and treatment-emergent peripheral neuropathy (PN).

Results

Among 368 patients (median [IQR] age, 68.0 [62.0-74.0] years; 267 male [72.6%] and 101 female [27.4%]), median (IQR) follow-up was 15.4 (8.4-20.0) months. Median PFS was 5.7 months in the reduced-dose group and 6.3 months in the full-dose group (adjusted hazard ratio [HR], 1.24; 95% CI, 0.95-1.61); median OS was 10.1 and 10.5 months, respectively (adjusted HR, 1.07; 95% CI, 0.81-1.43). Objective response occurred in 65 of 146 response-evaluable patients (44.5%) in the reduced-dose group and 95 of 179 (53.1%) in the full-dose group. Grade 3 or higher PN occurred in 6 of 170 reduced-dose patients (3.5%) and 20 of 198 full-dose patients (10.1%) (adjusted odds ratio, 0.26; 95% CI, 0.09-0.73). In post hoc analyses, reductions exceeding 20% were associated with shorter PFS compared with the full-dose group (adjusted HR, 1.40; 95% CI, 1.01-1.95), although the overall 3-group comparison was not statistically significant. Conclusions and Relevance In this multicenter cohort study, physician-selected initial EV dose reduction was not significantly associated with survival or response outcomes. These findings do not establish equivalence or warrant routine initial dose reduction. The lower incidence of severe PN and the exploratory PFS signal with reductions exceeding 20% are hypothesis-generating and require prospective validation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalCarcinoma, Transitional CellUrologic NeoplasmsDrug TaperingHumansFemaleRetrospective StudiesMaleMiddle AgedAgedTreatment OutcomeRepublic of KoreaProgression-Free SurvivalDose-Response Relationship, Drug

Substanzen

enfortumab vedotinAntibodies, Monoclonal

Autor:innen und Institutionen

  • Division of Medical Oncology, Department of Internal Medicine, Seoul St Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
  • Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Division of Medical Oncology, Ewha Womans University College of Medicine, Seoul, Republic of Korea.
  • Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea.
  • Division of Medical Oncology, Department of Internal Medicine, Gil Medical Center, College of Medicine, Gachon University, Incheon, Republic of Korea.
  • Division of Hematology-Oncology, Chonnam National University Medical School and Hwasun Hospital, Hwasun, Republic of Korea.

Zitieren

APA

Kim, I. H., Kim, C. G., Jo, J., Jung, E. H., Park, J. H., Bae, W. K., Huh, S. J., Choi, Y. J., Im, H. S., Lee, H. J., Lee, K., Lee, M. Y., Park, J. H., Kim, H. J., Song, H. N., Kim, H., Shin, S. H., & Park, I. (2026). Initial Enfortumab Vedotin Dose Reduction and Outcomes in Pretreated Advanced Urothelial Carcinoma. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2026.39846

Vancouver

Kim IH, Kim CG, Jo J, Jung EH, Park JH, Bae WK, et al. Initial Enfortumab Vedotin Dose Reduction and Outcomes in Pretreated Advanced Urothelial Carcinoma. JAMA Network Open. 2026. doi:10.1001/jamanetworkopen.2026.39846

BibTeX
@article{Kim2026,
  author = {Kim, In-Ho and Kim, Chang Gon and Jo, Jungmin and Jung, Eun Hee and Park, Joo-Hwan and Bae, Woo Kyun and Huh, Seok Jae and Choi, Yoon Ji and Im, Hyeon-Su and Lee, Hyo Jin and Lee, Kyoungmin and Lee, Min-Young and Park, Ji Hyun and Kim, Hee Jun and Song, Haa-Na and Kim, Hongsik and Shin, Seong-Hoon and Park, Inkeun},
  title = {Initial Enfortumab Vedotin Dose Reduction and Outcomes in Pretreated Advanced Urothelial Carcinoma},
  journal = {JAMA Network Open},
  year = {2026},
  doi = {10.1001/jamanetworkopen.2026.39846}
}
Kostenlos starten →